Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 hospitalized meta-analysis

Abd-Elsalam
 
NCT04353336
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
97/97 inconclusive 19%
Chen
 
NCT04384380
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
21/12 inconclusive -40%
Gonzalez (HCQ)
 
NCT04391127
RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
33/37 inconclusive -60% -28%
HAHPS
 
NCT04329832
RCThydroxychloroquineazithromycinCOVID 19 hospitalizedsome concern
42/43 inconclusive 540%
HYCOVID
 
NCT04325893
RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
124/123 inconclusive -41% 11%
NO COVID-19 (Lyngbakken)
 
NCT04316377
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
27/26 inconclusive -4%
ORCHID
 
NCT04332991
RCThydroxychloroquineplaceboCOVID 19 hospitalizedlow
242/237 inconclusive 6% 2% 12%
RECOVERY
 
NCT04381936
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
1561/3155 safety concern 8% 13%
SOLIDARITY (WHO study) HCQ
 
NCT04315948
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
947/906 inconclusive 17% 10%
TEACH
 
NCT04369742
RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
67/61 inconclusive 6%

COVID-19 mild to moderate meta-analysis

FACCT Trial
 
NCT04392973
RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
125/129 inconclusive -4%
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine
 
NCT04322123
RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
221/227 safety concern 42%

COVID-19 severe or critically meta-analysis

HYDRA (Hernandez-Cardenas)
 
NCT04315896
RCThydroxychloroquineplaceboCOVID-19 severe or criticallysome concern
106/108 inconclusive -18%
27 studies excluded by filtering options (15 RCT / 12 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).